Iasodopa

Fluorodopa, the active ingredient in Iasodopa, is a radiopharmaceutical presented as an injectable solution for intravenous use. The tracer is incorporated into PET protocols to visualize presynaptic dopamine synthesis, providing clinicians with quantitative data for treatment planning. It is employed to evaluate Parkinsonian syndromes and assess dopaminergic function in the brain, aiding the differential diagnosis of movement disorders.

GNH USA supplies Iasodopa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across global markets.

Fluorodopa is employed as a PET radiotracer to visualize presynaptic dopamine synthesis, supporting the clinical assessment of disorders that affect the dopaminergic pathways. - Parkinsonian syndromes: enables PET imaging to assess presynaptic dopamine synthesis and storage. - Differential diagnosis of movement disorders: helps distinguish Parkinson's disease from other tremor or dystonia conditions. - Assessment of dopaminergic function in the brain: provides quantitative data on dopamine synthesis for clinical evaluation. - Clinical research of neurodegenerative diseases: allows measurement of dopamine pathway activity in investigational studies.

Fluorodopa may be associated with adverse reactions related to its radiopharmaceutical nature and intravenous administration.

Common Side Effects: - Nausea: mild to moderate nausea reported after injection. - Headache: transient headache may occur. - Injection site discomfort: mild pain or erythema at the infusion site. - Transient hypotension: brief drop in blood pressure in some patients. - Flushing: temporary skin flushing observed in a minority of subjects.

Serious or Rare Side Effects: - Allergic reaction: anaphylaxis or severe hypersensitivity. - Radiation‑induced tissue injury: rare localized tissue effects from radiation exposure. - Severe hypotension: prolonged low blood pressure requiring intervention. - Nephrotoxicity: rare kidney function impairment. - Cardiac arrhythmia: rare occurrence of rhythm disturbances.

When using Fluorodopa, consider the following precautions to ensure patient safety and product integrity. - Pregnancy: use only if clearly needed, as fetal radiation exposure is unknown. - Breastfeeding: avoid breastfeeding for a period after administration due to possible radiotracer excretion. - Renal impairment: assess kidney function before dosing, as clearance may be reduced. - Concomitant medications: evaluate drugs affecting dopamine metabolism, such as carbidopa, which may alter tracer uptake. - Patient monitoring: observe vital signs and for allergic reactions during and after injection. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Fluorodopa can interact with certain substances that affect dopamine pathways or radiotracer distribution.

Major Interactions (Avoid): - Carbidopa or benserazide: potent inhibition of aromatic L‑amino acid decarboxylase reduces tracer conversion, compromising imaging. - Antipsychotics (e.g., haloperidol, risperidone): block dopamine receptors and may alter tracer uptake, affecting diagnostic accuracy.

Moderate Interactions (Monitor Closely): - MAO‑B inhibitors (e.g., selegiline): may increase fluorodopamine levels, potentially affecting image interpretation. - Antidepressants influencing dopamine (e.g., bupropion): could modify tracer distribution. - High‑dose levodopa therapy: competing substrate may reduce fluorodopa uptake.